Form 4: Neurocrine CSO Gifts Shares in Pre-Planned Move

Neurocrine Biosciences' Chief Scientific Officer, Jude Onyia, gifted 3,116 shares of common stock in a pre-planned transaction.

Summary

• Jude Onyia, Chief Scientific Officer of Neurocrine Biosciences Inc. (NBIX), disposed of 3,116 shares of common stock.
• The transaction occurred on August 5, 2025.
• The disposition was a gift/charitable contribution, with no monetary value received for the shares.
• Following this transaction, Jude Onyia beneficially owns 15,173 shares of common stock.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating it was pre-planned.

Sentiment

Score: 6

Explanation: The transaction is a gift, which is a personal decision by an insider and not directly indicative of company performance. The pre-planned nature (10b5-1) suggests a structured approach. While it reduces insider holdings, it's for a charitable purpose, which is generally viewed neutrally to slightly positively from a corporate governance perspective.

Positives

• The transaction was a gift/charitable contribution, which can reflect positively on the insider's philanthropic activities.
• The transaction was pre-planned under a Rule 10b5-1(c) plan, indicating a structured approach to share disposition rather than a reaction to immediate market conditions.

Negatives

• The insider's direct beneficial ownership of common stock decreased by 3,116 shares.

Industry Context

This filing is an insider transaction report and does not provide information relevant to broader industry trends or competitors.

Stakeholder Impact

• Shareholders: A very minor reduction in insider ownership, unlikely to have a material impact on the overall share structure or price.
• Employees: No direct impact.
• Customers: No direct impact.
• Suppliers: No direct impact.
• Creditors: No direct impact.

Key Dates

Recommendation

This Form 4 filing details a routine, pre-planned gift of shares by a Chief Scientific Officer. It does not provide any new information regarding the company's financial performance, strategic direction, or operational health that would warrant a change in investment recommendation. The transaction is a personal disposition and not indicative of a change in company fundamentals or outlook.

Keywords

Neurocrine Biosciences, NBIX, Jude Onyia, Chief Scientific Officer, CSO, Insider Transaction, Form 4, Stock Gift, Charitable Contribution, Rule 10b5-1